Clinical trials: AdV Infection
Bladder Cancer, High Grade
Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder Cancer
This is an expanded access protocol to study the safety and efficacy of CG0070 in Cis and Cis with Ta and/or T1 disease patients who failed both BCG therapy and the BOND protocol (NCT 01438112), or in high grade Ta and T1…
- Conditions
- Bladder Cancer, High Grade, Non Muscle Invasive
- Trial name
- exBOND (NCT02143804)
- Testing
- oncolytic adenovirus expressing GMCSF
- Where
- United States
- Sponsor
- CG Oncology, Inc.
ICH - Intracerebral Hemorrhage
Epidemiology of Intracerebral Hemorrhage
Exploring the risk factors and associations of intracerebral hemorrhage
- Trial name
- ICH (NCT06654544)
- Volunteers
- 60 people
- Sponsor
- Assiut University
COVID-19
A 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCINE TRIAL
This is a phase 2/3, multicenter, randomized, placebo-controlled, observer-blind study assessing the safety, tolerability, immunogenicity, and efficacy of prophylactic hAd5-S-Fusion+N-ETSD against COVID-19.
- Trial name
- NCT06022224
- Testing
- hAd5-S-Fusion+N-ETSD
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- ImmunityBio, Inc.
Cystitis, Bladder Diseases
Cidofovir Instillation in Hematopoietic Stem Cell Transplant (HSCT) Recipients With Hemorrhagic Cystitis
The goal of this clinical research study is to learn how the body absorbs and processes 1 dose of cidofovir that is given directly into the bladder, in patients with a viral infection that is causing bleeding from the bladder.
- Trial name
- NCT00956176
- Testing
- Cidofovir
- Sponsor
- M.D. Anderson Cancer Center
HIV Infections
Safety and Efficacy of a Three-Dose Regimen of an Adenoviral HIV Vaccine (MRKAd5 HIV-1 Gag/Pol/Nef) in HIV Uninfected South African Adults
The purpose of this study is to determine the safety, efficacy, and tolerability of a three-dose regimen of an adenovirus-based HIV-1 vaccine in healthy South African adults.
- Trial name
- NCT00413725
- Testing
- MRKAd5 HIV-1 gag/pol/nef
- Where
- 5 sites in South Africa
- Volunteers
- 801 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
A Study to Assess the Immunogenicity, Tolerability and Safety of a Malaria Vaccine and Also Its Protective Efficacy in a Malaria Challenge Model
The purpose of this study is to assess the safety, tolerability and immunogenicity of two dose levels (1x10^10 and 5x10^10 virus particles (vp)) of the adenovirus serotype (Ad) Ad35.CS.01/Ad26.CS.01 prime-boost malaria candidate…
- Trial name
- NCT01397227
- Testing
- Ad35.CS.01/Ad26.CS.01 low dose (1 x 10^10 vp), Ad 35.CS.01/Ad 26.CS.01 high dose (5 x 10^10 vp)
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Microbiome, Vaccine
Gut Microbiota, the Potential Key to Modulating Humoral Immunogenicity of New Platform COVID-19 Vaccines
Vaccination is the best way to mitigate the coronavirus disease 2019 (COVID-19) pandemic, but the vaccine immunogenicity may be quite variable from person to person.
- Conditions
- Microbiome, Vaccine, Covid-19, SARS-CoV-2
- Trial name
- NCT05150834
- Testing
- This is observational study
- Where
- South Korea
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Korea University Guro Hospital
Adenovirus Infections, Human
Incidence and Outcomes Associated With the Management of Adenovirus Infections in Allogenic Hematopoietic Cell Transplant Recipients
To depict the incidence, outcomes and standards of care (SoC) of adenovirus (AdV) infections and associated practice patterns in allogeneic hematopoietic cell transplant recipients.
- Trial name
- AdVance (NCT04285788)
- Volunteers
- 216 people
- Sponsor
- Jazz Pharmaceuticals
HIV-1-infection
A Study to Test Three Experimental HIV Vaccines in Healthy Adults.
HIV-CORE 006 is a Phase 1 double-blind placebo-controlled trial, in which the mosaic immunogens are delivered by a prime-boost regimen of non-replicating simian adenovirus followed by non-replicating poxvirus MVA.
- Trial name
- HIV-CORE 006 (NCT04553016)
- Testing
- Vaccine
- Where
- 4 sites in Kenya, Uganda and 1 more
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Healthy, HIV Infections
Safety and Immunogenicity of an HIV Vaccine in Normal Adult Volunteers
This study will test the safety of an experimental vaccine against HIV infection and see if it causes an immune response to HIV. The vaccine is given by injection (shot) in the upper arm.
- Trial name
- NCT00083330
- Testing
- VRC-HIVADV014-00-VP
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector)
This is a phase II, randomised, double-blinded and placebo-controlled clinical trial in healthy adults above 18 years of age. This clinical trial is designed to evaluate the immunogenicity and safety of Ad5-nCoV which encodes for…
- Trial name
- CTII-nCoV (NCT04341389)
- Testing
- Recombinant novel coronavirus vaccine (Adenovirus type 5 vector)
- Where
- China
- Volunteers
- 508 people, healthy volunteers welcome
- Sponsor
- Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China